您现在的位置:新特药 > 医药动态 > 意大利MolMed公司携手TIGET进军CAR-T疗法领域

意大利MolMed公司携手TIGET进军CAR-T疗法领域

新药编辑:新特药 更新时间:2015-04-19

2015年4月19日讯 /tumor.net.cn/ --如果十年后生物医药产业分析人士再回首,2014年、2015年或许将是一段值得大书特书的时期。在这两年中,随着生物医药产业的努力,肿瘤免疫疗法已经从一个概念逐渐变为现实。而在众多免疫疗法中,CAR-T疗法收获了业界最多的目光。随着这一概念的兴起,科学家们将有望利用免疫系统作为人类最有力的武器去对抗肿瘤病魔。

目前在这一领域中的领头羊当属诺华公司和Juno公司等。但是,由于看好这一领域巨大的前景,仍然有众多的生物医药公司纷纷挤入这一领域。最近,来自意大利的MolMed生物医药公司就成为这一领域最新的一位参赛者。

MolMed公司最近宣布,公司已经和意大利San Raffaele-Telethon Institute for Gene Therapy (TIGET)达成了合作协议共同开发新型CAR-T疗法CAR-CD44v6 。合约双方并未透露过多的合作细节,但研究人员表示这种疗法在小鼠模型上表现出了针对急性粒细胞白血病和多发性骨髓瘤的良好效果。这种药物主要靶向肿瘤细胞表面CD44信号分子的6型突变。因此,理论上只要与此相关的肿瘤类型都有可能会对这种疗法起到良好的反应。这也意味着许多血癌和实体瘤入肺癌和乳腺癌都是这种疗法的潜在适应症之一。而后两者也是当前肿瘤市场上患者人数最多的肿瘤类型之一。

进入2015年,CAR-T疗法又不断取得新进展。今年2月份,诺华公司与宾大联手开展CAR-T疗法治疗恶性胶质瘤的临床研究,将CAR-T疗法的应用进一步拓展;(相关阅读:再下一城,诺华-宾大即将开展CAR-T治疗恶性胶质瘤临床研究)随后本月初,CAR-T领域两大先锋诺华公司和Juno公司又宣布达成有关CAR-T疗法专利纷争和解,这为CAR-T在2015年继续飞速发展扫清了又一大法律障碍。(相关阅读:诺华、Juno低调了结专利纷争 CAR-T疗法开发最大法律障碍被扫除!)

可以预见,在未来相当长的一段时间内CAR-T疗法仍然是生物医药产业关注的焦点。(tumor.net.cn)

详细英文报道:

MolMed (BIT:MLM) has become the latest to buy its way into the CAR-T race. The deal sees it pick up assets from an immune-gene therapy CAR-CD44v6 project run by a group at San Raffaele Scientific Institute, the Milan-based research center that struck a deal with Biogen ($BIIB) in January.

Luigi Naldini, who heads up the San Raffaele-Telethon Institute for Gene Therapy (TIGET) with which Biogen partnered, played a role in the research program licensed by MolMed. Tests in mouse models have assessed the efficacy of the treatment against acute myeloid leukemia and multiple myeloma, but MolMed thinks there is the potential to branch out into a range of hematological and solid tumor indications. In theory, any cancer involving variant 6 of the CD44 antigen--a list which includes the above mentioned hematological indications and carcinomas of the breast and lung--is an option.

The hematological mouse model tests date back to 2013, at which time Naldini and his collaborators said the use of a chimeric antigen receptor with a CD28 signaling domain to target T cells at CD44v6 warranted investigation in clinical trials. MolMed is well placed to assess the strength of the project. The drugmaker struck a deal with San Raffaele Hospital in 2001 that gives it the option to pick up any gene and molecular therapies for oncology and AIDS that emerge from the research center. And it has taken an active interest in the progress of the CAR-CD44v6 project.

MolMed CEO Claudio Bordignon co-authored the CD44v6 paper with Naldini and a who's who of researchers from the Milanese gene therapy scene. "The CAR-CD44v6 project will benefit not only from our extensive experience and knowhow in the field of gene and cell therapy, but also from the conjugation with the suicide gene TK, becoming the first CAR-T product to integrate a control system already extensively tested and validated in clinical trials," Bordignon said in a statement.

The experience and knowhow to which Bordignon refers has started to attract attention. As well as the gene therapy deal with Biogen, TIGET is working with local startup Genenta Science on the targeted use of interferon against hematopoietic malignancies.

  • 新特药:http://www.tumor.net.cn/yydt/1449.html专稿,未经书面授权请勿转载。

  • 展开